Clinical Trials on Granuloma, Plasma Cell

Total 32330 results

Federal Research Institute of Pediatric Hematology...

Unknown

Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors

Inflammatory Myofibroblastic Tumor

Russian Federation
Hospital Angeles del Pedregal

Completed

"Outcomes of Surgical Removal of Foreign Body Granulomas"

Surgery | Complication | Foreign Body Granuloma

Mexico
Xuzhou Central Hospital

Completed

Low-dose Protocol for Computed Tomography-guided Lung Biopsy

Lung Cancer, Adenocarcinoma | Lung Inflammatory Pseudotumor

China
Princess Maxima Center for Pediatric Oncology
Takeda

Recruiting

Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors (Briga-PED)

Anaplastic Large Cell Lymphoma, ALK-Positive | Inflammatory Myofibroblastic Tumor | Other Solid Tumor

France, Netherlands
Takeda

Withdrawn

Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

Solid Tumors | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | Inflammatory Myofibroblastic Tumors
Shiraz University of Medical Sciences

Completed

Efficacy of Nasal Spray Calcitonin on Recurrence of Aggressive Central Giant Cell Granuloma

Central Giant Cell Granuloma

Iran, Islamic Republic of
Novartis Pharmaceuticals

Terminated

Ceritinib Rare Indications Study in ALK+ Tumors

Glioblastoma | Anaplastic Large Cell Lymphoma | Inflammatory Myofibroblastic Tumor | Tumors With Aberrations in ALK

France, Czechia, Italy, Spain, Korea, Republic of, Thailand, Israel, Denmark
Zeynep Kamil Maternity and Pediatric Research and...

Not yet recruiting

Predictive Value of Granulosa Cell DNA Damage in the Success of Assisted Reproductive Technique

DNA Damage | Granulosa Cells
Beni-Suef University

Recruiting

Corticosteroid Intralesional Injection as an Alternative Treatment in Oral Pyogenic Granuloma in the Esthetic Zone.

Oral Pyogenic Granuloma

Egypt
Alexandria University

Completed

Effectiveness of Diode Laser and Sclerotherapy in Treatment of Oral Pyogenic Granuloma

Pyogenic Granuloma of Gingiva

Egypt
Children Hospital and Institute of Child Health...

Completed

Silver Nitrate Versus Topical Steroid For Umbilical Granuloma

Umbilical Granuloma

Pakistan
Shaheed Zulfiqar Ali Bhutto Medical University

Completed

Comparison Of Doxycycline And Common Salt For Treatment Of Umbilical Granuloma: A Randomised Control Trial

Umbilical Granuloma

Pakistan
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Withdrawn

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM)

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present

United States
University of Zurich

Completed

Characterization of Laryngeal Contact Granulomas: Retrospective Analysis of Symptoms, Promotive Factors and Therapy

Laryngeal Contact Granuloma

Switzerland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
IRCCS Centro di Riferimento Oncologico della Basilicata
Celgene Corporation

Completed

Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia

Primary Plasma Cell Leukemia

Italy
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Refractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma | DS (Durie/Salmon) Stage I Plasma Cell Myeloma

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes...

Completed

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | ISS Stage III Plasma Cell Myeloma | ISS Stage II Plasma Cell Myeloma | ISS Stage I Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | Plasmacytoma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
Phillip Song, MD

Withdrawn

Efficacy Study of Botulinum Toxin (BOTOX) Injections to Treat Vocal Fold Granulomas

Granuloma | Contact Ulcer of Vocal Folds | Granuloma of Vocal Cords | Granuloma, Laryngeal

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

Plasma Cell Myeloma | Plasma Cell Leukemia in Remission

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Roswell Park Cancer Institute
Celgene

Active, not recruiting

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Plasma Cell Myeloma | Partial Response of Multiple Myeloma or Plasma Cell Leukemia

United States
National Cancer Institute (NCI)

Completed

FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Medical University of Graz

Recruiting

Evaluation of Cryotherapy in Granuloma Pyogenicum

Cryotherapy Effect | Granuloma, Pyogenic

Austria
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Adult Type Ovarian Granulosa Cell Tumor | Ovarian Gynandroblastoma | Ovarian Sertoli-Leydig Cell Tumor | Ovarian Sex Cord Tumor With Annular Tubules | Ovarian Steroid Cell Tumor

United States, Japan
Shaheed Zulfiqar Ali Bhutto Medical University

Completed

Double Ligation and Topical Silver Nitrate (RCT)

Umbilical Granuloma
National Cancer Institute (NCI)

Completed

Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia | Loss of Chromosome 17p | Autologous Hematopoietic Stem Cell Transplant Recipient

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation (PCL-2)

Plasma Cell Leukemia
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Plasma Cell Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Non-Secretory Plasma Cell Myeloma | Plasmacytosis

United States
University Health Network, Toronto

Completed

Luspatercept in Metastatic AGCT of the Ovary

Adult Granulosa Cell Tumor of the Ovary

Canada
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

Adult Ovarian Granulosa Cell Tumor

United States
Reproductive Medicine Associates of New Jersey

Completed

Evaluation of Discarded Laboratory Pathological Specimens and Media

Non-viable Oocytes | Extra Spermatozoa | Seminal Fluid | Granulosa Cells | Serum | Follicular Fluid | Conditioned IVF Media

United States
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

Plasma Cell Leukemia

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

Plasma Cell Leukemia

China
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Hematopoietic Cell Transplantation Recipient

United States
Mayo Clinic

Active, not recruiting

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma

United States
Roswell Park Cancer Institute

Recruiting

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic

Completed

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Roswell Park Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States

Clinical Trials on Granuloma, Plasma Cell

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations